Back to top

Analyst Blog

Recently, Warner Chilcott plc received encouraging news when the US Food and Drug Administration (FDA) approved its ulcerative colitis drug Delzicol (mesalamine). The company intends to launch the drug in Mar this year.

The approval will enable Warner Chilcott to market the drug in dosage of 400mg for treating patients suffering from mildly to moderately active ulcerative colitis and for the maintenance of remission of the disease.

We note that another distinguished ulcerative colitis drug in the company’s product portfolio is Asacol. This drug is marketed in 2 doses – 400 mg and 800 mg.

We are positive on the addition of a new product to Warner Chilcott’s product portfolio since many of its key drugs are facing declining sales due to generic competition. The generic competition that the company is currently facing or expects to face for its various drugs has put significant pressure on it.

Osteoporosis drug, Actonel lost exclusivity in Western Europe in late 2010. Actonel accounted for 70% of Warner Chilcott’s 2010 revenues from the region. Moreover, the company suffered a huge setback in 2012 when a US district court ruled that the generic versions of neither Mylan, Inc. (MYL - Analyst Report) nor Impax Laboratories Inc. (IPXL - Snapshot Report) infringed the patent of Warner Chilcott’s 150 mg dosage of acne drug Doryx.

Following the verdict, Mylan has entered into the US market with its generic version of Doryx 150 mg. Also, drugs such as Loestrin and Enablex are expected to go off patent in the US in 2014 and 2015, respectively. The genericization of key products will make it challenging for Warner Chilcott to drive the top line.

Warner Chilcott, a specialty pharmaceutical company, currently carries a Zacks Rank #3 (Hold). Valeant Pharmaceuticals International, Inc. (VRX - Analyst Report) is well placed in the specialty pharmaceutical space with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SOUTHWEST A… LUV 31.99 +2.40%
CHINA BIOLO… CBPO 47.40 +2.20%
MALLINCKROD… MNK 72.32 +1.97%
PLANAR SYST… PLNR 4.30 +1.78%
GILEAD SCIE… GILD 103.80 +1.50%